RNAC vs. RNA, GPCR, ACAD, TGTX, RYTM, BHC, JANX, INDV, DCPH, and MRVI
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Avidity Biosciences (RNA), Structure Therapeutics (GPCR), ACADIA Pharmaceuticals (ACAD), TG Therapeutics (TGTX), Rhythm Pharmaceuticals (RYTM), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Indivior (INDV), Deciphera Pharmaceuticals (DCPH), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
87.0% of Cartesian Therapeutics shares are held by institutional investors. 61.1% of Cartesian Therapeutics shares are held by insiders. Comparatively, 3.7% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cartesian Therapeutics has a net margin of -983.93% compared to Avidity Biosciences' net margin of -2,103.78%. Avidity Biosciences' return on equity of -37.98% beat Cartesian Therapeutics' return on equity.
Avidity Biosciences received 126 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Cartesian Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
In the previous week, Avidity Biosciences had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 8 mentions for Avidity Biosciences and 7 mentions for Cartesian Therapeutics. Avidity Biosciences' average media sentiment score of 0.83 beat Cartesian Therapeutics' score of 0.75 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Avidity Biosciences has lower revenue, but higher earnings than Cartesian Therapeutics.
Cartesian Therapeutics presently has a consensus price target of $45.00, suggesting a potential upside of 23.02%. Avidity Biosciences has a consensus price target of $41.33, suggesting a potential upside of 55.39%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Cartesian Therapeutics.
Summary
Avidity Biosciences beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
